Targets › MYB
2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Jul 2027.
Transcriptional activator; DNA-binding protein that specifically recognize the sequence 5'-YAAC[GT]G-3'. Plays an important role in the control of proliferation and differentiation of hematopoietic progenitor cells. (UniProt, P10242)
Open in Phaseline: the race on MYB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Remix Therapeutics | REM-422 MYB mRNA degrader | MYB | Phase 1 | Myelodysplastic Syndromes; Adenoid Cystic Carcinoma | Jul 2027 |
| Rgenta Therapeutics | RGT-61159 MYB inhibitor | MYB | Phase 1 | Adenoid Cystic Carcinoma | Dec 2027 |
Adenoid Cystic Carcinoma (2) Myelodysplastic Syndromes (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.